Celltrion’s 4 new biosimilars win EU approval recommendation

Q: How long will it take to read this news story?

The story "Celltrion’s 4 new biosimilars win EU approval recommendation" has 327 words across 25 sentences, which will take approximately 2 - 3 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Celltrion’s 4 new biosimilars win EU approval recommendation" was covered 2 hours ago by Korea Economic Daily, a news publisher based in South Korea.

Q: How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news. The outlet is headquartered in South Korea and publishes an average of 8 news stories per day. It's most recent story was published 5 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #24430502</li><li>URL: https://beamstart.com/news/celltrions-4-new-biosimilars-win-17343471854610</li></ul>

Korea Economic Daily Logo Korea Economic Daily 2h ago

Celltrion’s 4 new biosimilars win EU approval recommendation - Korea Economic Daily

Quick Summary:

The company estimates the global markets for the four biosimilars at around 135 trillion won ($94 billion) combined Celltrion said it is rare that the CHMP recommended approval of four products from a single company simultaneously, which recognized its technology and development capabilities.

Celltrion Inc.is a step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) recommended approval for the drugs.

The four new biosimilars will beef up Celltrion’s product lineup for inflammatory autoimmune disease treatments on which it has focused and also diversify into new segments such as bone cancer and eye disease drugs.